exatecan Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(F)c(C)c3c1c2[C@@H](N)CC3.CS(=O)(=O)O.O.O
  • InChIKey: FXQZOHBMBQTBMJ-MWPGLPCQSA-N
  • Mol. Mass: 567.59
  • ALogP: 2.47
  • ChEMBL Molecules:
    exatecan mesylate  
    exatecan  
    None  
More Chemistry

Pharmacology

Alternative names

(1s,9s)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1h,12h-benzo(de)pyrano(3',4'-6,7)indolizino(1,2-b)quinoline-10,13(9h,15h)dione methanesulfonate | dx 8951 | dx-8951 | dx-8951a | dx 8951f | dx-8951f | exatecan | exatecan hydrochloride | exatecan mesylate | exatecan (mesylate)

Organizations (7)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Bile Duct Neoplasms (Phase 2)

Brain Neoplasms (Phase 1)

Breast Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Gallbladder Neoplasms (Phase 2)

Hamartoma (Phase 2)

Leukemia (Phase 1)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 2)

Sarcoma (Phase 2)

Stomach Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue